Skip to content

Study of Infrared Thermography in Diabetic Foot in Guadeloupe

Study of Infrared Thermography in Diabetic Foot in Guadeloupe (ETPDG)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07040488
Acronym
ETPDG
Enrollment
150
Registered
2025-06-27
Start date
2024-09-27
Completion date
2026-03-27
Last updated
2025-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Infection

Keywords

Infrared thermography, diabetic foot, infection

Brief summary

It is hypothesized that thermal imaging differs between diabetic and non-diabetic individuals in Guadeloupe. Infrared thermography is also suggested as a useful tool for studying diabetic foot ulceration. The main objective is to compare the temperatures of four areas of the plantar surface of the foot among non-diabetic individuals, diabetic individuals, and diabetic individuals with foot ulceration.

Detailed description

Diabetes represents a major public health issue in the region. Among its most severe complications is diabetic foot ulceration, which frequently results in amputation. Infrared thermography is a non-invasive and non-ionizing imaging technique that provides precise temperature data at specific points on the body. When combined with 3D imaging technologies, infrared thermography may offer early diagnostic potential for infections related to diabetic foot ulcers, by revealing both visible and subclinical signs. A preliminary step in assessing the relevance of thermal imaging is to determine whether thermographic patterns differ between the feet of diabetic and non-diabetic individuals within the Guadeloupean population, particularly in a tropical climate. Currently, international guidelines do not recommend infrared thermography as part of routine clinical practice for managing diabetic foot ulceration. However, this imaging modality could potentially contribute to the diagnostic arsenal for infections associated with diabetic foot ulcers.

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire de la Guadeloupe
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

for Control Group * Adult patients * Patients of Afro-Caribbean origin * Volunteer patients free from pathology * Person affiliated to or beneficiary of a social security scheme. * Person who has agreed to sign a consent to participate in the study Inclusion Criteria for diabetic patients: * Adult patients * Patients of Afro-Caribbean origin * Type 1 or type 2 diabetic patients with and without diabetic foot ulceration * Person affiliated to or beneficiary of a social security system. * Person who has agreed to sign a consent to participate in the study

Exclusion criteria

: * \- Minors * patient with an active fracture or a history of fracture * a history of legs surgery * History of amputation * Bilateral diabetic ulceration * neurological disease (Parkinson, stroke, etc.) * pregnancy * Foot mycosis * refusal of consent

Design outcomes

Primary

MeasureTime frameDescription
temperatures at four areas of the plantar surface of the footbaselineThe primary outcome is the measurement of temperatures in degrees Celsius (°C) using infrared thermography (coupled with a 3D camera) at four areas of the plantar surface of the foot: the pulp of the hallux, the heel, the heads of the first and fifth metatarsals, and at the site of the diabetic foot ulcer.

Secondary

MeasureTime frameDescription
Temperatures on the same area of the contralateral footbaselineTemperatures in degrees Celsius (°C) at the level of the ulceration of the diabetic foot and on the same area of the contralateral foot

Countries

Guadeloupe

Contacts

Primary ContactMélanie petapermal
melanie.petapermal@chu-guadeloupe.fr+590590934667

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026